In a subgroup of high-risk Asians, telmisartan was non-inferior to ramipril and better tolerated in the prevention of cardiovascular events.
Results of the recently published ONTARGET study (The Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial) showed that telmisartan (80 mg/day) was non-inferior to ramipril (10 mg/day) in reducing cardiovascular events. Clinicians in Asia doubt tolerability of these doses...
Main Authors: | Antonio L Dans, Koon Teo, Peggy Gao, Jyh-Hong Chen, Kim Jae-Hyung, Khalid Yusoff, Suphachai Chaithiraphan, Jun Zhu, Liu Lisheng, Salim Yusuf, Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial Investigators |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2010-12-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC3006195?pdf=render |
Similar Items
-
In a subgroup of high-risk asians, telmisartan was non-inferior to ramipril and better tolerated in the prevention of cardiovascular events
by: Chaithiraphan, S., et al. -
In a Subgroup of High-Risk Asians, Telmisartan Was Non-Inferior to Ramipril and Better Tolerated in the Prevention of Cardiovascular Events
by: Chaithiraphan, S, et al. -
Comparative Efficacy and Safety of Triple Therapy (Ramipril, Telmisartan, Hydrochlorothiazide) Vs Dual Anti Hypertensive Therapy (Ramipril or Telmisartan, Hydrochlorothiazide) in Stage 2 Hypertensive Patients
by: Bharat Bhushan, et al.
Published: (2014-08-01) -
Prevention and intervention studies with telmisartan, ramipril and their combination in different rat stroke models.
by: Christa Thoene-Reineke, et al.
Published: (2011-01-01) -
Telmisartán, ramipril y su combinación en pacientes de alto riesgo vascular
by: Gabriel Waisman
Published: (2008-07-01)